MedPath

KAWAKAMI ATSUSHI

🇯🇵Japan
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

16

Active:4
Completed:5

Trial Phases

5 Phases

Phase 1:1
Phase 2:3
Phase 3:3
+2 more phases

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (16 trials with phase data)• Click on a phase to view related trials

Phase 4
7 (43.8%)
Phase 2
3 (18.8%)
Phase 3
3 (18.8%)
Not Applicable
2 (12.5%)
Phase 1
1 (6.3%)

Discontinuation of Methotrexate in Rheumatoid Arthritis Patients Achieving Clinical Remission by Treatment With Upadacitinib Plus Methotrexate

Phase 3
Recruiting
Conditions
Rheumatoid Arthritis
JAK Inhibitor
Biomarker
Musculoskeletal Ultrasound
Interventions
First Posted Date
2021-11-16
Last Posted Date
2021-12-08
Lead Sponsor
Atsushi Kawakami
Target Recruit Count
155
Registration Number
NCT05121298
Locations
🇯🇵

Nagasaki University Hospital, Nagasaki, Japan

Efficacy and Safety of Selective JAK 1 Inhibitor Filgotinib in Active Rheumatoid Arthritis Patients With Inadequate Response to Methotrexate

Phase 3
Conditions
Musculoskeletal Ultrasound
Biomarker
Rheumatoid Arthritis
IL-6 Inhibitor
JAK Inhibitor
Interventions
First Posted Date
2021-10-22
Last Posted Date
2021-11-01
Lead Sponsor
Atsushi Kawakami
Target Recruit Count
400
Registration Number
NCT05090410
Locations
🇯🇵

Nagasaki University Hospital, Nagasaki, Japan

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.